Artificial Intelligence
April 23–25, 2018
Boston, MA • United States

Past Forums

2015 Summary

“We need a clear, cohesive vision of how to link the fruits of innovation with the patients who should no longer have to suffer through painful lives or fear a premature death. We need to bring the best minds in health care together to address how we can encourage and incentivize new neurological discoveries and how we can leverage innovation to make our world a better place.”

With those words, Partners HealthCare CEO David Torchiana, MD opened the first annual World Medical Innovation Forum, an event that led many of health care’s most important leaders and transformative thinkers to converge in Boston this April to share their visions of neurological medicine’s future. The Forum was unique among the nation’s calendar of health care conferences and summits, in the breadth and depth of subject matter discussed as well as the senior standing of those participating. The Forum gathered nearly 1,000 clinicians, researchers, investors, entrepreneurs and health care industry leaders from 25 states and 18 countries. Together, they provided and absorbed information on game-changing technologies, devices, drugs and therapies that will elevate the way we diagnose, treat and care for neurodegenerative and psychiatric disorders.

Snapshots from the Forum include:

  • U.S. Health and Human Services Secretary Sylvia Mathews Burwell shared information with Forum participants on the Obama Administration’s new initiative on precision medicine.
  • The active participation of leading CEOs from the health insurance, health information technology, pharmaceutical and medical device industries, including Jeff Immelt of General Electric, Robert Bradway of Amgen, Mark Bertolini of Aetna, Mike Mahoney of Boston Scientific, Jeff Leiden MD, PhD of Vertex Pharmaceuticals and George Scangos, PhD of Biogen, who shared details of his company’s exciting progress on treatments for Alzheimer’s Disease.
  • Many of the nation’s top journalists served as moderators, asking the probing questions of speakers and panelists that led to illuminating insights. Moderators included former NBC News Chief Medical Editor Nancy Snyderman, MD, Kyra Phillips, CNN Correspondent, John Roberts, Senior National Correspondent, Fox News, Meg Tirell, CNBC Biotech and Pharma Reporter, Alice Park, Writer, TIME Magazine, Jonathan LaPook, MD, Chief Medical Correspondent, CBS Evening News and Michelle Cortez, Reporter, Bloomberg Businessweek.
  • Former First Lady of Massachusetts Ann Romney not only discussed her own experience as a multiple sclerosis patient, but also the hope and promise embodied in the new Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital.
  • Medicine’s premier thought leaders, like Brigham and Women’s Atul Gawande, MD, discussed how today’s health care systems can accommodate and encourage emerging, evolving scientific knowledge.

2015 Keynoters

Robert Bradway, CEO, Amgen
Robert Bradway

CEO, Amgen

Kyra Phillips
Kyra Phillips

Anchor and Correspondent, CNN

George Scangos, CEO, Biogen Idec
George Scangos PhD

CEO, Biogen

Jeff Leiden, MD, PhD, Chairman, CEO, Vertex Pharmaceuticals
Jeffrey Leiden MD, PhD

CEO, Vertex Pharmaceuticals

David Meeker, MD
David Meeker MD

CEO, Genzyme

Deborah Dunsire, CEO, Forum Pharmaceuticals
Deborah Dunsire MD

CEO, Forum Pharmaceuticals

Peter Orszag PhD

Vice Chairman, Corporate and Investment Banking, Citigroup

Rudy Tanzi, PhD, Harvard Medical School
Rudolph Tanzi PhD

Director, Genetics and Aging Research Unit, MGH Institute for Neurodegenerative Disease
Joseph P. and Rose F. Kennedy Professor of Child Neurology and Mental Retardation, Harvard Medical School

Atul Gawande, MD, Surgeon, Brigham and Women’s Hospital
Atul Gawande MD

Executive Director, Ariadne Labs
General and Endocrine Surgery, BWH, Professor of Surgery, Harvard Medical School

Ann Romney
Ann Romney

Global Ambassador, Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital

2015 Panels

Day One: Monday, April 27, 2015
Discovery Café: Sharing Perspectives

Welcome

  • David Torchiana, MD
    CEO, Partners HealthCare
  • Anne Klibanski, MD
    Chief Academic Officer, Partners HealthCare; Laurie Carrol Guthart Professor of Medicine, Harvard Medical School

Neurocare, Neuromarkets, and Neuro Challenges

  • Jonathan LaPook, MD
    Chief Medical Correspondent, CBS News
  • Antonio Chiocca, MD, PhD
    Chairman, Neurosurgery, Brigham and Women’s Hospital; Harvey W. Cushing Professor of Neurosurgery, Harvard Medical School
  • Merit Cudkowicz, MD
    Chairman, Neurology, Massachusetts General Hospital; Julieanne Dorn Professor of Neurology, Harvard Medical School
  • Scott Rauch, MD
    President and Psychiatrist in Chief, McLean Hospital; Rose-Marie and Eijk van Otterloo Chair of Psychiatry, Harvard Medical School

Over the Horizon: Witnessing the Disruption of Neurocare

  • Alice Park
    Writer, TIME Magazine
  • Ajay Verma, MD, PhD
    Vice President of Experimental Medicine, Biogen
  • Geoffrey Ling, MD, PhD
    Director, Biological Technologies Office, DARPA
  • Moncef Slaoui, PhD
    Chairman of Global R&D and Vaccines, GlaxoSmithKline

Transformation and Innovation: Conflict? Collision? Opportunity?

  • Nancy Snyderman, MD
    Chief Medical Editor, NBC News (ret.)
  • Jeff Leiden, MD, PhD
    CEO, Vertex Pharmaceuticals
  • Mike Mahoney
    CEO, Boston Scientific
  • Betsy Nabel, MD
    President, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School
  • George Scangos, PhD
    CEO, Biogen
  • Peter Slavin, MD
    President, Massachusetts General Hospital; Professor of Healthcare Policy, Harvard Medical School

Gene to Drug: Kansas to Oz, Making it Happen in the Real World

  • Jonathan LaPook, MD
    Chief Medical Correspondent, CBS News
  • David Altshuler, MD, PhD
    Executive Vice President of Global Research and CSO, Vertex Pharmaceuticals
  • Mark Fishman, MD
    President, Novartis Institutes for BioMedical Research
  • Jeffrey Gulcher, MD, PhD
    Co-Founder and CSO WuXi NextCODE
  • Sean Harper, MD
    Executive Vice President, Research and Development, Amgen

Welcome Reception

  • Dinner Program – Jeff Immelt
  • Edward Lawrence
    Chairman, Board of Directors, Partners HealthCare
  • Nancy Snyderman, MD
    Chief Medical Editor, NBC News (ret.)
  • Jeff Immelt
    CEO, General Electric

Day Two: Tuesday, April 28, 2015

Clinical Demonstrations: Neuroswitch and AMIGO Suite

  • David Storto
    President, Partners Continuing Care, Spaulding Rehabilitation Network
  • Merit Cudkowicz, MD
    Chairman, Neurology, Massachusetts General Hospital; Julieanne Dorn Professor of Neurology, Harvard Medical School
  • Antonio Chiocca, MD, PhD
    Chairman, Neurosurgery, Brigham and Women’s Hospital; Harvey W. Cushing Professor of Neurosurgery, Harvard Medical School
  • Peter Ford
    Founder and CEO, Control Bionics
  • Nathalie Agar, PhD
    Neuroscientist, Brigham and Women’s Hospital, Assistant Professor of Radiology, Harvard Medical School
  • Alexandra Golby, MD
    Director, Image-Guided Neurosurgery, Brigham and Women’s Hospital, Associate Professor of Radiology, Harvard Medical School

Patient One-On-One — Ann Romney

  • Scott Sperling
    Co-President, Thomas H. Lee Partners, Chairman, Board of Trustees, Brigham and Women’s Hospital
  • Nancy Snyderman, MD
    Chief Medical Editor, NBC News (ret.)
  • Ann Romney
    Global Ambassador, Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital

The Alzheimer’s Phoenix: New Technologies, New Economics

  • Rudolph Tanzi, PhD
    Director, Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease & Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School
  • Michael Hutton, PhD
    CSO, Neurodegenerative Diseases, Eli Lilly & Co.
  • Brad Hyman, MD, PhD
    Director, Massachusetts General Hospital Alzheimer’s Disease Research Center; John B. Penney Professor of Neurology, Harvard Medical School
  • Roger Nitsch, PhD
    Director, Division of Psychiatry Research, University of Zurich
  • Dale Schenk, PhD
    CEO, Prothena
  • Dennis Selkoe, MD
    Co-Director, Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital; Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical School

Regeneration, Cell Therapy, and Neurocare: Products? Delivery?

  • Alice Park
    Writer, TIME Magazine
  • Ole Isacson, MD
    Director, Center for Neuroregeneration Research/Neuroregeneration Laboratories, McLean Hospital; Professor of Neurology, Harvard Medical School
  • Martin McGlynn
    CEO, StemCells
  • Doug Melton, PhD
    Xander University Professor, Harvard University; Investigator, Howard Hughes Medical Institute; Co-Chair Department of Stem Cell and Regenerative Biology
  • David Scadden, MD
    Director, Center for Regenerative Medicine, Massachusetts General Hospital; Gerald and Darlene Jordan Professor of Medicine, Harvard Medical School

CEO One-On-One

  • Cathy Minehan
    Dean, School of Management, Simmons College, Chair, Board of Trustees, Massachusetts General Hospital
  • Meg Tirrell
    Biotech & Pharma Reporter, CNBC
  • Robert Bradway
    CEO, Amgen

Lunch Program — George Scangos

  • Peter Slavin, MD
    President, Massachusetts General Hospital; Professor of Healthcare Policy, Harvard Medical School
  • Kyra Phillips
    Anchor and Correspondent, CNN
  • George Scangos, PhD
    CEO, Biogen

Lunch Program - Hon. Sylvia Matthews Burwell

  • David Torchiana, MD
    CEO, Partners HealthCare
  • Hon. Sylvia Matthews Burwell
    Secretary, US Department of Health & Human Services

Neurostimulation: First Line Therapy?

  • Peter Ford
    Founder and CEO, Control Bionics
  • Emad Eskandar, MD
    Neurosurgeon, Massachusetts General Hospital; Charles Pappas Professor of Neurosurgery, Harvard Medical School
  • Frank Fischer
    CEO, NeuroPace
  • Lothar Krinke, PhD
    Vice President and General Manager, Brain Modulation, Medtronic
  • Ben Pless
    CEO, ATI
  • Mark Demitrack, MD
    Chief Medical Officer, Neuronetics

Olympus Explained: Neuroinvesting for Mortals

  • Meg Tirrell
    Biotech & Pharma Reporter, CNBC
  • Doug Cole, MD
    General Partner, Flagship Ventures
  • Jean-François Formela, MD
    Partner, Atlas Ventures
  • Corey Goodman, PhD
    Managing Partner, venBio
  • Rajiv Kaul
    Select Biotechnology Portfolio and Advisor Biotechnology Fund, Fidelity Investments
  • Sue Siegel
    CEO, GE Ventures & healthymagination

National Security Through Neurodevelopment: Country Initiatives to Meet CNS Challenges

  • John Roberts
    Senior National Correspondent, Fox News
  • Miri Polachek
    Executive Director, Israel Brain Technologies
  • Michael Hodin, PhD
    Executive Director, Global Coalition on Aging; Managing Partner, High Lantern Group
  • Tom Large, PhD
    Senior Vice President, Preclinical Research and Translational Medicine, Sunovion Pharmaceuticals
  • Luc Truyen, MD, PhD
    Vice President, Neuroscience External Affairs, Chair, Johnson & Johnson Global Fight Against Alzheimer’s Disease

Technology, Pathology, Radiology: Changing the Game through Neurodiagnostics

  • Jerrold Rosenbaum, MD
    Psychiatrist-In-Chief; Stanley Cobb Professor of Psychiatry, Harvard Medical School
  • Jeffrey Golden, MD
    Chairman, Department of Pathology, Brigham and Women’s Hospital; Ramzi S. Cotran Professor of Pathology, Harvard Medical School
  • Jeff Hersh, MD, PhD
    Chief Medical Officer, GE Healthcare
  • David Louis, MD
    Pathologist-in-Chief, Massachusetts General Hospital; Benjamin Castleman Professor of Pathology, Harvard Medical School
  • Bruce Rosen, MD, PhD
    Director, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital; Professor of Radiology, Harvard Medical School

Autism and Neurodevelopment: Are Therapies Possible Today?

  • Ron Suskind
    Pulitzer Prize-winning Journalist and Author, Director of the Project on Public Narrative, Harvard University
  • Randall Carpenter, MD
    Translational Medicine Consultant; Research Affiliate, Department of Brain and Cognitive Sciences, MIT
  • Mark Daly, PhD
    Chief, Analytic and Translational Genetics, Massachusetts General Hospital; Associate Professor of Medicine, Harvard Medical School
  • Christopher McDougle, MD
    Director, Lurie Center for Autism, Massachusetts General Hospital for Children; Nancy Lurie Marks Professor of Autism, Harvard Medical School
  • Ricardo Dolmetsch, PhD
    Global Head of Neuroscience, Novartis Institutes for Biomedical Research
  • Bob Wright
    Co-Founder, Autism Speaks; Senior Advisor, Lee Equity Partners

Psychiatric Targets: Finally New Mechanisms?

  • Gideon Gil
    Health and Science Editor, The Boston Globe
  • Deborah Dunsire, MD
    CEO, FORUM Pharmaceuticals
  • Mike Ehlers, MD, PhD
    Neuroscience Chief Science Officer, Pfizer
  • Maurizio Fava, MD
    Executive Vice Chair, Massachusetts General Hospital Psychiatry; Slater Family Professor of Psychiatry, Harvard Medical School
  • Corey McCann, MD, PhD
    Founder and CEO, Pear Therapeutics
  • David Silbersweig, MD
    Chairman, Psychiatry, Brigham and Women’s Hospital; Stanley Cobb Professor of Psychiatry, Harvard Medical School

Sleep and Consciousness: Clinical Need Versus Safety

  • Martha Bebinger
    Reporter, WBUR
  • Matt Bianchi, MD, PhD
    Chief, Division of Sleep Medicine, and Director, Sleep Laboratory, Massachusetts General Hospital Neurology; Assistant Professor of Neurology, Harvard Medical School
  • Charles Czeisler, PhD, MD
    Brigham and Women’s Hospital Medicine and Neurology; Baldino Professor of Sleep Medicine, Harvard Medical School
  • Patrick Purdon PhD
    Associate Bioengeneer, Massachusetts General Hospital - Department of Anesthesia, Critical Care, and Pain Medicine; Instructor of Anaesthesia, Harvard Medical School
  • Darryle Schoepp, PhD
    Vice President & Therapeutic Area Head, Neuroscience, Merck Research Laboratories

Parkinson’s: Finally Crossing the Therapeutic Threshold

  • Michelle Cortez
    Reporter, Bloomberg Businessweek
  • Frank Bennett, PhD
    Senior Vice President of Research, Isis Pharmaceuticals
  • Michael Schwarzschild, MD, PhD
    Chair, Parkinson Study Group (PSG) Executive Committee, MassGeneral Institute for Neurodegenerative Disease; Professor of Neurology, Harvard Medical School
  • Clemens Scherzer, MD
    Director, Neurogenomics Lab and Parkinson Personalized Medicine Program, Brigham and Women’s Hospital/Massachusetts General Hospital; Associate Professor of Neurology, Harvard Medical School
  • Todd Sherer, PhD
    CEO, The Michael J. Fox Foundation for Parkinson’s Research

New Leaders at the Table: Filling the Gap Through Philanthropy?

  • David Shenk
    Author, lecturer, filmmaker, Senior Advisor, Cure Alzheimer’s Fund
  • Meryl Comer
    President, Geoffrey Beene Foundation Alzheimer’s Initiative
  • Henry McCance
    Chairman Emeritus, Greylock Partners, Co-Founder, Cure Alzheimer’s Fund
  • Bill Sahlman
    Dimitri V. D’Arbeloff - MBA Class of 1955 Professor of Business Administration, Senior Associate Dean for External Relations, Harvard Business School
  • Steven Tregay
    CEO, Forma Therapeutics
  • Nancy and Pete Frates
    The Pete Frates #3 Fund, Champions, ALS Ice Bucket Challenge
  • Jeff Walker
    Vice Chair, United Nations Envoy’s Office for Health Finance and Malaria

Day Three: Wednesday, April 29, 2015

Reshaping Innovation Through Electronic Health

  • Gregg Meyer, MD
    Chief Clinical Officer, Partners HealthCare
  • Judy Faulkner
    CEO and Founder, EPIC Systems

Gene Editing, Gene Therapy, and the Eye as a Gateway

  • Jennifer Joe, MD
    CEO, Medstro, Editor-In-Chief, MedTech Boston
  • Katrine Bosley
    CEO, Editas Medicine
  • Eric Pierce, MD, PhD
    Director, Retinal Degenerations Service, Massachusetts Eye and Ear; Solman and Libe Friedman Associate Professor of Ophthalmology, Harvard Medical School
  • Philip Gregory, D. Phil
    Senior Vice President, Research and CSO, Sangamo BioSciences
  • David Meeker, MD
    CEO, Genzyme

MS Transformed: Harnessing Biology and Inflammation

  • Mallika Marshall, MD
    Medical Reporter, WBZ-TV Boston
  • Tim Coetzee, PhD
    Chief Advocacy, Services, and Research Officer, National Multiple Sclerosis Society
  • Al Sandrock, MD, PhD
    Group Senior Vice President, Chief Medical Officer, Biogen
  • Howard Weiner, MD
    Founder and Director, Partners Multiple Sclerosis Center; Robert L. Kroc Professor of Neurology, Harvard Medical School
  • Michael Panzara, MD
    Group Vice President, Therapeutic Area Head, Multiple Sclerosis and Neurology, Genzyme

The Disruptive Dozen: 12 Technologies That Will Reinvent Neurocare

  • Rudolph Tanzi, PhD
    Director, Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease & Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School
  • David Silbersweig, MD
    Chairman, Brigham and Women’s Hospital Psychiatry; Stanley Cobb Professor of Psychiatry, Harvard Medical School

The Century of the Molecule Becomes The Century of the System

  • Marshall Moriarty
    Retired Chair, Brigham and Women’s Hospital, Board of Trustees
  • Atul Gawande, MD
    Executive Director, Ariadne Labs; General and Endocrine Surgery, BWH; Professor of Surgery, Harvard Medical School

The Builder’s Roundtable: Perspectives of Public/Private Payer Architects

  • Tim Ferris, MD
    Senior Vice President, Population Health Management
  • Mark Bertolini
    Chairman and CEO, Aetna
  • Peter Orszag
    Vice Chairman, Corporate and Investment Banking, Citigroup

Closing Remarks and Preview of 2016 World Forum

  • Duke Collier
    President, The Braxton Company
  • Anne Klibanski, MD
    Chief Academic Officer, Partners HealthCare; Laurie Carrol Guthart Professor of Medicine, Harvard Medical School

Stakeholder

Boston Scientific logo

Strategic

amgen
Lilly footer
ge
Pfizer footer

Collaborators

Astra Zeneca - Footer
Bayer - Footer
CR Bard
Edwards footer
Medtronic footer
Mintz Levin footer
Novo Nordisk
STAT footer